Polypharmacology Shakes Hands with Complex Aetiopathology

Trends in Pharmacological Sciences

Volumn 36, Issue 12, 2015, Pages 802-821

  Brodie, James S ^a   Di Marzo, Vincenzo ^b   Guy, Geoffrey W ^a  

^a Porton Down Science Park   (United Kingdom)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ETIRACETAM; NABIXIMOLS; VALPROIC ACID;

CANCER PAIN; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EPILEPSY; ETIOLOGY; GENETIC REGULATION; HUMAN; INFLAMMATORY BOWEL DISEASE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYPHARMACOLOGY; PRIORITY JOURNAL; REVIEW; SPASTICITY; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL MODEL; COMBINATION DRUG THERAPY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; DRUG THERAPY, COMBINATION; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; POLYPHARMACOLOGY;

EID: 84949503244     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.08.010     Document Type: Review

References (159)

1. F. Bosch, and L. Rosich The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize Pharmacology 82 2008 171 179
2. M.M. Hann, and T.I. Oprea Pursuing the leadlikeness concept in pharmaceutical research Curr. Opin. Chem. Biol. 8 2004 255 263
3. J.P. Hughes, and et al. Principles of early drug discovery Br. J. Pharmacol. 162 2011 1239 1249
4. N.A. Listed Recent pa-tent applications in high-throughput drug screening Nat. Biotechnol. 28 2010 329
5. H.F. Ji, and et al. Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep. 10 2009 194 200
6. A. Fleming Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae by Alexander Fleming, Reprinted from the British Journal of Experimental Pathology 10:226-236, 1929 Rev. Infect. Dis. 2 1980 129 139
7. H. Shapiro, and et al. Polyphenols in the prevention and treatment of sepsis syndromes: rationale and pre-clinical evidence Nutrition 25 2009 981 997
8. J. Gonzalez-Gallego, and et al. Fruit polyphenols, immunity and inflammation Br. J. Nutr. 104 Suppl. 3 2010 S15 S27
9. A. Cuevas, and et al. Modulation of immune function by polyphenols: possible contribution of epigenetic factors Nutrients 5 2013 2314 2332
10. M.E. Baker Xenobiotics and the evolution of multicellular animals: emergence and diversification of ligand-activated transcription factors Integr. Comp. Biol. 45 2005 172 178
11. M.D. Rawlins Variability in response to drugs Br. Med. J. 4 1974 91 94
12. Q. Ma, and A.Y. Lu Pharmacogenetics, pharmacogenomics, and individualized medicine Pharmacol. Rev. 63 2011 437 459
13. P. Farahani, and M. Levine Pharmacovigilance in a genomic era Pharmacogenomics J. 6 2006 158 161
14. M.D. Rawlins Cutting the cost of drug development? Nat. Rev. Drug Discov. 3 2004 360 364
15. H.G. Eichler, and et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma Nat. Rev. Drug Discov. 7 2008 818 826
16. I. Kola The state of innovation in drug development Clin. Pharmacol. Ther. 83 2008 227 230
17. M.J. Keiser, and et al. Predicting new molecular targets for known drugs Nature 462 2009 175 181
18. V.C. Jordan Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer Br. J. Pharmacol. 110 1993 507 517
19. F. Armani, and et al. Tamoxifen use for the management of mania: a review of current preclinical evidence Psychopharmacology 231 2014 639 649
20. J.J. Lu, and et al. Multi-target drugs: the trend of drug research and development PLoS ONE 7 2012 e40262
21. A. Petrelli, and S. Giordano From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage Curr. Med. Chem. 15 2008 422 432
22. H. Zheng, and et al. From single target to multitarget/network therapeutics in Alzheimer's therapy Pharmaceuticals (Basel) 7 2014 113 135
23. G.R. Zimmermann, and et al. Multi-target therapeutics: when the whole is greater than the sum of the parts Drug Discov. Today 12 2007 34 42
24. P. Csermely, and et al. The efficiency of multi-target drugs: the network approach might help drug design Trends Pharmacol. Sci. 26 2005 178 182
25. H.T. Hussain, and et al. Clinical trial success rates of anti-obesity agents: the importance of combination therapies Obes. Rev. 16 2015 707 714
26. A.J. Garber, and et al. Aace/Ace comprehensive diabetes management algorithm 2015 Endocr. Pract. 21 2015 438 447
27. C. Arauz-Pacheco, and et al. Treatment of hypertension in adults with diabetes Diabetes Care 26 Suppl. 1 2003 S80 S82
28. K.A. Spratt Managing diabetic dyslipidemia: aggressive approach J. Am. Osteopath. Assoc. 109 2009 S2 S7
29. A.M. Scott, and et al. Antibody therapy of cancer Nat. Rev. Cancer 12 2012 278 287
30. M. Vanneman, and G. Dranoff Combining immunotherapy and targeted therapies in cancer treatment Nat. Rev. Cancer 12 2012 237 251
31. H.M. Shepard, and et al. Herceptin Handb. Exp. Pharmacol. 181 2008 183 219
32. G.K. Lambert, and et al. The background, discovery and clinical development of BCR-ABL inhibitors Drug Discov. Today 18 2013 992 1000
33. C. Chen, and et al. Editorial: Signalling pathways in anti-cancer drug resistance Curr. Med. Chem. 21 2014 3007 3008
34. B.L. Roth, and et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev. Drug Discov. 3 2004 353 359
35. N. Phougat, and et al. Combination therapy: the propitious rationale for drug development Comb. Chem. High Throughput Screen. 17 2014 53 67
36. C.N. Saha, and S. Bhattacharya Intellectual property rights: an overview and implications in pharmaceutical industry J. Adv. Pharm. Technol. Res. 2 2011 88 93
37. R.W. Humphrey, and et al. Opportunities and challenges in the development of experimental drug combinations for cancer J. Natl. Cancer Inst. 103 2011 1222 1226
38. E. Dolgin Longer exclusivity sought for fixed-dose drug combinations Nat. Med. 19 2013 1075
39. J. Woodcock, and et al. Development of novel combination therapies N. Engl. J. Med. 364 2011 985 987
40. M.A. Lindsay Target discovery Nat. Rev. Drug Discov. 2 2003 831 838
41. G.L. Verdine, and L.D. Walensky The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members Clin. Cancer Res. 13 2007 7264 7270
42. L.O. Schwen, and et al. Spatio-temporal simulation of first pass drug perfusion in the liver PLoS Comput. Biol. 10 2014 e1003499
43. G.M. Thurber, and R. Weissleder A systems approach for tumor pharmacokinetics PLoS ONE 6 2011 e24696
44. T. Kenakin Functional selectivity through protean and biased agonism: who steers the ship? Mol. Pharmacol. 72 2007 1393 1401
45. T. Kenakin Functional selectivity and biased receptor signaling J. Pharmacol. Exp. Ther. 336 2011 296 302
46. G. Derosa, and P. Maffioli Anti-obesity drugs: a review about their effects and their safety Expert Opin. Drug Saf. 11 2012 459 471
47. R.G. Pertwee Inverse agonism and neutral antagonism at cannabinoid CB1 receptors Life Sci. 76 2005 1307 1324
48. M.A. Steiner, and C.T. Wotjak Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis Prog. Brain Res. 170 2008 397 432
49. C.J. Hillard Stress regulates endocannabinoid-CB1 receptor signaling Semin. Immunol. 26 2014 380 388
50. R.J. Chorvat Peripherally restricted CB1 receptor blockers Bioorg. Med. Chem. Lett. 23 2013 4751 4760
51. D.R. Janero, and A. Makriyannis Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis Expert Opin. Emerg. Drugs 14 2009 43 65
52. J.A. Lieberman Dopamine partial agonists: a new class of antipsychotic CNS Drugs 18 2004 251 267
53. V.V. Uteshev The therapeutic promise of positive allosteric modulation of nicotinic receptors Eur. J. Pharmacol. 727 2014 181 185
54. N.T. Burford, and et al. Discovery of positive allosteric modulators and silent allosteric modulators of the mu-opioid receptor Proc. Natl. Acad. Sci. U.S.A. 110 2013 10830 10835
55. T. Tomson, and G. Kenneback Arrhythmia, heart rate variability, and antiepileptic drugs Epilepsia 38 1997 S48 S51
56. S. Bacchi, and et al. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review Antiinflamm. Antiallergy Agents Med. Chem. 11 2012 52 64
57. R.J. Flower The development of COX2 inhibitors Nat. Rev. Drug Discov. 2 2003 179 191
58. A.K. Chakraborti, and et al. Progress in COX-2 inhibitors: a journey so far Curr. Med. Chem. 17 2010 1563 1593
59. B. Schmid, and et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: randomized placebo-controlled, double blind clinical trial Phytother. Res. 15 2001 344 350
60. ® (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data Expert Rev. Neurother. 11 2011 15 19
61. P. Robson Human studies of cannabinoids and medicinal cannabis R. Pertwee, Cannabinoids 2005 Springer 719 756
62. J. Fernandez-Ruiz, and et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br. J. Clin. Pharmacol. 75 2013 323 333
63. I.G. Karniol, and E.A. Carlini Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol Psychopharmacologia 33 1973 53 70
64. I.G. Karniol, and et al. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man Eur. J. Pharmacol. 28 1974 172 177
65. D. Baker, and et al. The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis Mult. Scler. Relat. Disord. 1 2012 64 75
66. A. Mukherjee, and A. Chakravarty Spasticity mechanisms - for the clinician Front. Neurol. 1 2010 149
67. T. Rekand Clinical assessment and management of spasticity: a review Acta Neurol. Scand. 122 Suppl. 190 2010 62 66
68. V. Di Marzo Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight Nat. Neurosci. 14 2011 9 15
69. D. Baker, and et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model Nature 404 2000 84 87
70. E. de Lago, and et al. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake Eur. J. Pharmacol. 484 2004 249 257
71. A. Ligresti, and et al. New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis Br. J. Pharmacol. 147 2006 83 91
72. G. Pryce, and et al. Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors Mult. Scler. 19 2013 1896 1904
73. D. Baker, and et al. Endocannabinoids control spasticity in a multiple sclerosis model FASEB J. 15 2001 300 302
74. T. Bisogno, and et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide Br. J. Pharmacol. 134 2001 845 852
75. J. Ahrens, and et al. The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-Beta glycine receptor function Pharmacology 83 2009 217 222
76. E. Murillo-Rodriguez, and et al. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study Sleep 26 2003 943 947
77. F.A. Iannotti, and et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability ACS Chem. Neurosci. 5 2014 1131 1141
78. V. Di Marzo, and L. Cristino Why endocannabinoids are not all alike Nat. Neurosci. 11 2008 124 126
79. A. Hilliard, and et al. Evaluation of the effects of Sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: a model of multiple sclerosis ISRN Neurol. 2012 2012 802649
80. M. Russo, and et al. Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation Neural Plast. 2015 2015 656582
81. R.M. Langford, and et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis J. Neurol. 260 2013 984 997
82. D.J. Rog, and et al. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial Clin. Ther. 29 2007 2068 2079
83. R.K. Portenoy, and et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial J. Pain 13 2012 438 449
84. J.R. Johnson, and et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain J. Pain Symptom Manage. 39 2010 167 179
85. J.R. Johnson, and et al. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics J. Pain Symptom Manage. 46 2013 207 218
86. E. Palazzo, and et al. Moving towards supraspinal TRPV1 receptors for chronic pain relief Mol. Pain 6 2010 66
87. C. Giordano, and et al. TRPV1-dependent and -independent alterations in the limbic cortex of neuropathic mice: impact on glial caspases and pain perception Cereb. Cortex 22 2012 2495 2518
88. A. Kornbluth, and D.B. Sachar Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee Am. J. Gastroenterol. 99 2004 1371 1385
89. J.D. Feuerstein, and A.S. Cheifetz Ulcerative colitis: epidemiology, diagnosis, and management Mayo Clin. Proc. 89 2014 1553 1563
90. W.A. Faubion Jr, and et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study Gastroenterology 121 2001 255 260
91. R.P. MacDermott, and et al. The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease Inflamm. Bowel Dis. 4 1998 54 67
92. S. Danese New therapies for inflammatory bowel disease: from the bench to the bedside Gut 61 2012 918 932
93. P. Irving, and et al. P414 Cannabidiol for symptomatic treatment of ulcerative colitis: results from a randomised, double-blind, placebo-controlled, parallel group, multi-centred pilot study 10th Congress of the European Crohn's and Colitis Organisation (ECCO) ECCO 2015
94. S. Russ, and et al. A national profile of childhood epilepsy and seizure disorder Pediatrics 129 2012 256 264
95. P. Kwan, and M.J. Brodie Early identification of refractory epilepsy N. Engl. J. Med. 342 2000 314 319
96. C. Dravet The core Dravet syndrome phenotype Epilepsia 52 Suppl. 2 2011 3 9
97. GW Pharmaceuticals GW Pharmaceuticals Initiates Second Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome 2015 GW Pharmaceuticals
98. N.A. Jones, and et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo J. Pharmacol. Exp. Ther. 332 2010 569 577
99. N.A. Jones, and et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures Seizure 21 2012 344 352
100. B.E. Porter, and C. Jacobson Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy Epilepsy Behav. 29 2013 574 577
101. K.K. Selmer, and et al. Parental SCN1A mutation mosaicism in familial Dravet syndrome Clin. Genet. 76 2009 398 403
102. P. De Jonghe Molecular genetics of Dravet syndrome Dev. Med. Child Neurol. 53 Suppl. 2 2011 7 10
103. I.O. Miller, and M.A. Sotero de Menezes SCN1A-Related Seizure Disorders 1993 University of Washington
104. W. Loscher Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy CNS Drugs 16 2002 669 694
105. B.A. Lynch, and et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proc. Natl. Acad. Sci. U.S.A. 101 2004 9861 9866
106. A. Shrivastava, and et al. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy Mol. Cancer Ther. 10 2011 1161 1172
107. X.F. Meng, and et al. Role of the mTOR signaling pathway in epilepsy J. Neurol. Sci. 332 2013 4 15
108. A.J. Hill, and et al. Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se Neurosci. Lett. 566 2014 269 274
109. L. De Petrocellis, and et al. Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes Br. J. Pharmacol. 163 2011 1479 1494
110. L.E. Gonzalez-Reyes, and et al. TRPV1 antagonist capsazepine suppresses 4-AP-induced epileptiform activity in vitro and electrographic seizures in vivo Exp. Neurol. 250 2013 321 332
111. F.J. Sun, and et al. Increased expression of TRPV1 in the cortex and hippocampus from patients with mesial temporal lobe epilepsy J. Mol. Neurosci. 49 2013 182 193
112. H.F. Shu, and et al. Expression of TRPV1 in cortical lesions from patients with tuberous sclerosis complex and focal cortical dysplasia type IIb Brain Dev. 35 2013 252 260
113. R.G. Pertwee The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin Br. J. Pharmacol. 153 2008 199 215
114. B. Coomber, and et al. Inhibition of endocannabinoid metabolism attenuates enhanced hippocampal neuronal activity induced by kainic acid Synapse 62 2008 746 755
115. J.O. Malva, and et al. Presynaptic modulation controlling neuronal excitability and epileptogenesis: role of kainate, adenosine and neuropeptide Y receptors Neurochem. Res. 28 2003 1501 1515
116. K.H. Yang, and et al. The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes J. Pharmacol. Exp. Ther. 333 2010 547 554
117. A.C. Campos, and F.S. Guimaraes Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats Psychopharmacology 199 2008 223 230
118. W.H. Theodore, and et al. Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy Epilepsia 53 2012 129 133
119. G. Esposito, and et al. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement PLoS ONE 6 2011 e28668
120. L. Walter, and et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration J. Neurosci. 23 2003 1398 1405
121. H. Yu, and et al. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data PLoS ONE 7 2012 e37608
122. R.H. Shoemaker The NCI60 human tumour cell line anticancer drug screen Nat. Rev. Cancer 6 2006 813 823
123. J. Lamb The Connectivity Map: a new tool for biomedical research Nat. Rev. Cancer 7 2007 54 60
124. L. Yetukuri, and et al. Informatics and computational strategies for the study of lipids Mol. Biosyst. 4 2008 121 127
125. E. Fahy, and et al. Update of the LIPID MAPS comprehensive classification system for lipids J. Lipid Res. 50 Suppl. 2009 S9 S14
126. J. Zhao, and et al. Predicting cooperative drug effects through the quantitative cellular profiling of response to individual drugs CPT Pharmacometrics Syst. Pharmacol. 3 2014 e102
127. A.A. Borisy, and et al. Systematic discovery of multicomponent therapeutics Proc. Natl. Acad. Sci. U.S.A. 100 2003 7977 7982
128. P.K. Wong, and et al. Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm Proc. Natl. Acad. Sci. U.S.A. 105 2008 5105 5110
129. T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 70 2010 440 446
130. J.C. Boik, and R.A. Newman A classification model to predict synergism/antagonism of cytotoxic mixtures using protein-drug docking scores BMC Pharmacol. 8 2008 13
131. H.A. Barton, and et al. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond Expert Opin. Drug Metab. Toxicol. 9 2013 459 472
132. J.R. Pritchard, and et al. Defining principles of combination drug mechanisms of action Proc. Natl. Acad. Sci. U.S.A. 110 2013 E170 E179
133. O. Koch Use of secondary structure element information in drug design: polypharmacology and conserved motifs in protein-ligand binding and protein-protein interfaces Future Med. Chem. 3 2011 699 708
134. Z. Wu, and et al. A systems biology approach to identify effective cocktail drugs BMC Syst. Biol. 4 Suppl. 2 2010 S7
135. X.M. Zhao, and et al. Prediction of drug combinations by integrating molecular and pharmacological data PLoS Comput. Biol. 7 2011 e1002323
136. S. Li, and et al. An effective solution to discover synergistic drugs for anti-cerebral ischemia from traditional Chinese medicinal formulae PLoS ONE 8 2013 e78902
137. R. Garcia-Serna, and J. Mestres Anticipating drug side effects by comparative pharmacology Expert Opin. Drug Metab. Toxicol. 6 2010 1253 1263
138. D. Potter The Propagation, Characterisation and Optimisation of Cannabis sativa L as a Phytopharmaceutical 2009 PhD thesis, King's College London
139. Center for Drug Evaluation and Research Guidance for Industry: Botanical Drug Products 2004 U.S. Department of Health and Human Services, Food and Drug Administration
140. E.P. de Meijer, and et al. The inheritance of chemical phenotype in Cannabis sativa L Genetics 163 2003 335 346
141. E.P.M. de Meijer, and K.M. Hammond The inheritance of chemical phenotype in Cannabis sativa L. (II): cannabigerol predominant plants Euphytica 145 2005 189 198
142. E.P.M. de Meijer, and et al. The inheritance of chemical phenotype in Cannabis sativa L. (III): variation in cannabichromene proportion Euphytica 165 2009 293 311
143. E.P.M. de Meijer, and et al. The inheritance of chemical phenotype in Cannabis sativa L. (IV): cannabinoid-free plants Euphytica 168 2009 95 112
144. K.W. Hillig, and P.G. Mahlberg A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae) Am. J. Bot. 91 2004 966 975
145. A.A. Izzo, and et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb Trends Pharmacol. Sci. 30 2009 515 527
146. R. Mechoulam Cannabinoids as Therapeutics 2006 Springer
147. V. Di Marzo, and et al. The endocannabinoid system and its therapeutic exploitation Nat. Rev. Drug Discov. 3 2004 771 784
148. J.M. McPartland, and et al. Are cannabidiol and Delta(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system?. A systematic review Br. J. Pharmacol. 172 2015 737 753
149. P.H. Reggio The Cannabinoid Receptors 2008 Humana
150. A.M. Malfitano, and et al. What we know and do not know about the cannabinoid receptor 2 (CB2) Semin. Immunol. 26 2014 369 379
151. M.H. Jantti, and et al. Autocrine endocannabinoid signaling through CB1 receptors potentiates OX1 orexin receptor signaling Mol. Pharmacol. 83 2013 621 632
152. W.I. Jeong, and et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver Cell Metab. 7 2008 227 235
153. T.F. Gamage, and A.H. Lichtman The endocannabinoid system: role in energy regulation Pediatr. Blood Cancer 58 2012 144 148
154. J. Guindon, and A.G. Hohmann The endocannabinoid system and cancer: therapeutic implication Br. J. Pharmacol. 163 2011 1447 1463
155. R. Mechoulam, and L.A. Parker The endocannabinoid system and the brain Annu. Rev. Psychol. 64 2013 21 47
156. R.G. Pertwee, and et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2) Pharmacol. Rev. 62 2010 588 631
157. L. Alanko, and et al. Localization of equilibrative nucleoside transporters in the rat brain J. Chem. Neuroanat. 31 2006 162 168
158. F. Borrelli, and et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease Biochem. Pharmacol. 85 2013 1306 1316
159. ® Treatment Effect in Children and Young Adults with Treatment-Resistant Epilepsy 2015 GW Pharmaceuticals